ISSN: 2378-3176 UNOAJ

Urology & Nephrology Open Access Journal
Editorial
Volume 1 Issue 1 - 2014
Fluorescein Angiography and Contrast Induced Nephropathy
Mohamed Essam*
Kidney and Urology Center, Egypt
Received:October 21, 2014 | Published: October 22, 2014
*Corresponding author: Mohamed Essam, Kidney and Urology Center, Egypt, Tel: +2-01005038467; Email: @
Citation: Essam M (2014) Fluorescein Angiography and Contrast Induced Nephropathy.Urol Nephrol Open Access J 1(1): 00005. DOI: 10.15406/unoaj.2014.01.00005

Abbreviations

DM: Diabetes Mellitus; CKD: Chronic Kidney Disease; CIN: Contrast Induced Nephropathy; CM: contrast Media; eGFR: estimated GFR

Editorial

Fluorescein angiography is a commonly used procedure for diagnosis and staging of diabetic retinopathy [1]. Diabetic retinopathy is one of the major complications of type 2 Diabetes Mellitus (DM). Patients with diabetic retinopathy are likely to have Chronic Kidney Disease (CKD) as degree of retinopathy correlates with the degree of nephropathy in diabetes [2].
Contrast Induced Nephropathy (CIN) is nowadays defined as an increase of 25% or more in serum creatinine, or an absolute increase of 0.5 mg/dl or more from baseline value, at 48-72 h following the exposure to Contrast Media (CM) [3].
Although several studies reported the effect of iodinated contrast media on kidney functions especially in diabetic CKD patients, however very few conflicting data had been published regarding fluorescein (non iodinated dye) induced renal injury.
One study in Japan didn’t find any effect of fluorescein angiography on renal functions using estimated GFR (eGFR) [4], however another study in Iran demonstrated anon significant rise of serum creatinine after fluorescein angiography in diabetic patients [5].
Our current practice tell us that fluorescein is generally safe on the kidneys, but evidence is still lacking to proof such concept and we still get notified because of a diabetic patient who need to do fluorescein angiography and has renal impairment.
Further research is therefore required to assess the safety of fluorescein angiography on renal functions in type 2 diabetic patients. May the use of early biomarkers and non dependence on serum creatinine be helpful in resolving the problem and reveal the mystery.

References

  1. Stingu C, Cristescu A, Daraban C, Serghiescu S (2003) [Fluorescein angiography in diabetic retinopathy]. Oftalmologia 56(1): 15-19.
  2. Wessing A (1997) Diabetic retinopathy: update on diagnosis and treatment. Nephrol Dial Transplant 12(9): 2013-2018.
  3. Mehran R, Nikolsky E (2006) Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 100: 11-15.
  4. Kameda Y, Babazono T, Haruyama K, Iwamoto Y, Kitano S (2009) Renal function following fluorescein angiography in diabetic patients with chronic kidney disease. Diabetes Care 32(3): e31.
  5. Alemzadeh-Ansari MJ, Beladi-Mousavi SS, Feghhei M (2011) Effect of fluorescein on renal function among diabetic patients. Nefrologia 31(5): 612-613.
© 2014-2016 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://medcraveonline.com
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy